Progenics Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PROGENICS PHARMS INC, and when can generic versions of PROGENICS PHARMS INC drugs launch?
PROGENICS PHARMS INC has two approved drugs.
There are five US patents protecting PROGENICS PHARMS INC drugs.
There are seventy-six patent family members on PROGENICS PHARMS INC drugs in twenty-three countries and seven supplementary protection certificates in seven countries.
Summary for Progenics Pharms Inc
| International Patents: | 76 |
| US Patents: | 5 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Progenics Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | 11,851,407 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | 10,947,197 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | 8,487,129 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | 8,778,305 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Progenics Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3699162 | ⤷ Try a Trial |
| European Patent Office | 3222615 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2017214470 | ⤷ Try a Trial |
| Japan | 2021095407 | ⤷ Try a Trial |
| Netherlands | 301250 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Progenics Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2318366 | LUC00323 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: PIFLUFOLASTAT (18F) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/23/1746 20230725 |
| 2318366 | 2023C/540 | Belgium | ⤷ Try a Trial | PRODUCT NAME: PIFLUFOLASTAT (18F) OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/23/1746 20230725 |
| 2318366 | 37/2023 | Austria | ⤷ Try a Trial | PRODUCT NAME: PIFLUFOLASTAT (18F) ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1746 (MITTEILUNG) 20230725 |
| 2318366 | C20230027 00410 | Estonia | ⤷ Try a Trial | PRODUCT NAME: PIFLUFOLASTAAT (18F);REG NO/DATE: EU/1/23/1746 25.07.2023 |
| 2318366 | CR 2023 00032 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PIFLUFOLASTAT (18F) ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/23/1746 20230725 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
